XML 44 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Quarterly Financial Information (Unaudited)
 12 Months Ended
Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]  
Quarterly Financial Information (Unaudited)
Quarterly Financial Information (Unaudited)
The following information has been derived from unaudited consolidated statements that, in the opinion of management, include all recurring adjustments necessary for a fair statement of such information.
 
Three Months Ended
 
March 31,
2018
 
June 30,
2018
 
September 30,
2018
 
December 31, 2018 (1)
Total revenues
$
39,666

 
$
45,275

 
$
32,448

 
$
43,185

Operating loss
(52,522
)
 
(49,735
)
 
(66,471
)
 
(336,882
)
Net loss
(47,409
)
 
(66,829
)
 
(58,746
)
 
(341,722
)
Net loss attributable to Intrexon
(46,165
)
 
(65,382
)
 
(57,324
)
 
(340,465
)
Net loss attributable to Intrexon per share, basic and diluted
$
(0.36
)
 
$
(0.51
)
 
$
(0.44
)
 
$
(2.59
)
(1)
During the fourth quarter of 2018, the Company reacquired certain in-process research and development from ZIOPHARM, Ares Trading, and Intrexon T1D Partners, all of which were immediately expensed (Notes 4 and 5). The Company also recorded an intangible asset impairment charge and a loss on abandonment of certain of its intangible assets (Note 11). The Company also recognized the remaining balance of deferred revenue associated with Histogenics and Synthetic Biologics upon the mutual termination of the ECCs with these entities (Note 17).
 
Three Months Ended
 
March 31,
2017
 
June 30,
2017
 
September 30,
2017
 
December 31, 2017 (1)
Total revenues
$
53,504

 
$
54,433

 
$
46,016

 
$
77,028

Operating loss
(31,381
)
 
(35,270
)
 
(44,747
)
 
(26,492
)
Net loss
(32,377
)
 
(19,662
)
 
(40,836
)
 
(33,945
)
Net loss attributable to Intrexon
(31,399
)
 
(18,664
)
 
(39,689
)
 
(27,266
)
Net loss attributable to Intrexon per share, basic and diluted
$
(0.26
)
 
$
(0.16
)
 
$
(0.33
)
 
$
(0.23
)

(1)
During the fourth quarter of 2017, the Company recognized the remaining balance of deferred revenue associated with ZIOPHARM ECC2 upon the parties' mutual agreement to terminate (Note 5). The Company also recorded goodwill impairment charges primarily related to the AquaBounty reporting unit and an impairment charge related to certain of its in-process research and development assets (Note 11).